A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2009
11/12/2009	US20090281135 3-azabicyclo [4. 1. 0] heptane derivatives for the treatment of depression
11/12/2009	US20090281129 Cdki pathway inhibitors and uses thereof
11/12/2009	US20090281128 Caspase inhibitors and uses thereof
11/12/2009	US20090281121 SUBSTITUTED 8-PIPERIDINYL-2-PYRIDINYL-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE AND 8-PIPERIDINYL-2-PYRIMIDINYL-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE DERIVATIVES
11/12/2009	US20090281116 Pyrrole derivatives, preparation thereof and therapeutic use thereof
11/12/2009	US20090281114 Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
11/12/2009	US20090281112 Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
11/12/2009	US20090281109 Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
11/12/2009	US20090281107 Substituted 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same
11/12/2009	US20090281103 Renin Inhibitors
11/12/2009	US20090281092 Polo-like kinase inhibitors
11/12/2009	US20090281086 2 -oxyheteroarylamide derivatives as parp inhibitors
11/12/2009	US20090281078 Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders
11/12/2009	US20090281077 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers
11/12/2009	US20090281066 Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones
11/12/2009	US20090281061 Impaired Alleles of Genes Involved in Metabolic Pathways and Methods for Detecting and Using the Same
11/12/2009	US20090281046 Cyclopropanated Carbohydrates
11/12/2009	US20090281045 Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
11/12/2009	US20090281036 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins
11/12/2009	US20090281031 Methods and Compositions Related to Improving Properties of Pharmacological Agents Targeting Nervous System
11/12/2009	US20090280564 Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells
11/12/2009	US20090280530 Novel collagen-like protein clac, precursor thereof and genes encoding the same
11/12/2009	US20090280199 Neuroprotective Compositions and Methods of Using Same
11/12/2009	US20090280195 Methods for the treatment of addictive disease and addiction to chemical substances and addictive behaviors using a formula containing the following formulation: Mucuna pruiens, N Acetyl L Cysteine, Magnesium Citrate
11/12/2009	US20090280192 Method for treating or preventing alzheimer's disease
11/12/2009	US20090280187 Oxidation-Stable Granulate Containing Unsaturated Fatty Acids
11/12/2009	US20090280176 Controlled release formulations of alprazolam
11/12/2009	US20090280117 Methods for the treatment or prevention of immune disorders using anti-cd40 antibodies
11/12/2009	US20090280114 Prevention of brain inflammation as a result of induced autoimmune response
11/12/2009	US20090280097 Pluripotent cells
11/12/2009	CA2726866A1 Methods and compositions for the treatment of huntington's disease
11/12/2009	CA2725546A1 Methods for preventing and treating neurodegenerative diseases
11/12/2009	CA2723685A1 Oral administration of peripherally-acting opioid antagonists
11/12/2009	CA2723679A1 Muscarinic receptor agonists useful in the treatment of pain, alzheimer's disease and schizophrenia
11/12/2009	CA2723440A1 Sulfobetaines for therapy
11/12/2009	CA2723146A1 Allosteric enhancers of the a1 adenosine receptor
11/12/2009	CA2722805A1 Trisubstituted pyrazoles as acetylcholine receptor modulators
11/12/2009	CA2722776A1 Nmda receptor antagonists for the treatment of neuropsychiatric disorders
11/12/2009	CA2722606A1 Urea compounds as gamma secretase modulators
11/12/2009	CA2722374A1 Method for treating cognitive deficits
11/12/2009	CA2721815A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
11/12/2009	CA2721786A1 Novel class of spiro piperidines for the treatment of neurodegenerative diseases
11/12/2009	CA2721433A1 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
11/12/2009	CA2721303A1 Azetidines and cyclobutanes as histamine h3 receptor antagonists
11/11/2009	EP2116556A1 Antibodies to receptor of advanced glycation end products (rage) and uses thereof
11/11/2009	EP2116547A1 Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands
11/11/2009	EP2116546A1 Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
11/11/2009	EP2116544A2 Spirocyclic cyclohexane derivatives
11/11/2009	EP2116541A1 Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
11/11/2009	EP2116538A1 Condensed tetrahydroquinoline derivative and use thereof for medical purposes
11/11/2009	EP2116526A1 Derivates of substituted tartaric aicd and usage for preparating beta secretase inhibitors
11/11/2009	EP2116264A1 Preparation for transnasal application
11/11/2009	EP2116255A1 Therapeutic agent for spinal cord injury
11/11/2009	EP2116252A1 The use of epimedium flavones and effective components thereof for the preparation of medicaments of promoting proliferations and differentiations of nerve cells
11/11/2009	EP2116250A1 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
11/11/2009	EP2116247A2 Anti-amnesia compounds and pharmaceutical compositions comprising same
11/11/2009	EP2116240A1 Augmented cognitive training with HT0712
11/11/2009	EP2116238A1 Amino acid composition
11/11/2009	EP2116236A1 Bisbenzamidine derivatives for use as antioxidant
11/11/2009	EP2116139A1 Sialic acid to support brain health in the elderly
11/11/2009	EP2114970A1 Tricyclic compounds and their use as glucocorticoid receptor modulators
11/11/2009	EP2114922A1 Substituted oxindole derivative and its use as a vasopressin receptor modulator
11/11/2009	EP2114894A1 Heterocyclyl-substituted-ehylamino-phenyl derivatives, their preparation and use as medicaments
11/11/2009	EP2114893A1 Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands
11/11/2009	EP2114888A1 Tricyclic compounds and their use as glucocorticoid receptor modulators
11/11/2009	EP2114878A1 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
11/11/2009	EP2114870A1 Synthetic ion channels
11/11/2009	EP2114862A1 Process for the preparation of o-desmethyl venlafaxine
11/11/2009	EP2114439A1 Use of somatostatin analogs in cluster headache
11/11/2009	EP2114437A2 Modified corticotropin releasing factor peptides and uses thereof
11/11/2009	EP2114436A1 Trkb agonists for treating autoimmune disorders
11/11/2009	EP2114411A2 Composition and method for protecting mitochondria
11/11/2009	EP2114158A1 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
11/11/2009	EP2114130A2 Animal model for adhd
11/11/2009	EP2007753B1 Heterocyclic gaba alpha subtype selective receptor modulators
11/11/2009	EP1960401B1 Tricyclic amide derivatives useful for treating obesity
11/11/2009	EP1915379B1 Olanzapine analogs and methods of use thereof
11/11/2009	EP1863464B1 O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
11/11/2009	EP1831189B1 Tetralin and indane derivatives and uses thereof
11/11/2009	EP1761492B1 1-benzyl-4-¬(5,6-dimethoxy-1-indanone)-2-yl methyl piperidine oxalate (donepezil oxalate) and its polymorphs
11/11/2009	EP1594868B1 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
11/11/2009	EP1557407B1 Novel alpha-ketoamide derivatives and use thereof
11/11/2009	EP1537104B1 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
11/11/2009	EP1430896B1 Nicotine-containing film preparation
11/11/2009	EP1401451B1 Quinazoline derivatives which promote the release of parathyroid hormone
11/11/2009	EP1397351B1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
11/11/2009	EP1372634B1 Use of fumaric acid amides
11/11/2009	EP1320369B1 A method of analgesia
11/11/2009	EP1315812B1 Modified polypeptides stabilized in a desired conformation and methods for producing same
11/11/2009	EP1242118B1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
11/11/2009	EP1191943B1 Anti-allergic peptides
11/11/2009	CN101578271A 4-imidazolines as TAAR's ligands
11/11/2009	CN101578269A N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g.
11/11/2009	CN101578100A Use of neuroprotective compounds for obtaining drugs for treating neurodegenerative diseases
11/11/2009	CN101578096A Robust sustained release formulations
11/11/2009	CN101578095A Robust sustained release formulations
11/11/2009	CN101578094A Robust sustained release formulations of oxymorphone and methods of use thereof
11/11/2009	CN101575341A Amidocyanogen amido xanthone pyridine derivant, and preparation method and application thereof
11/11/2009	CN101575336A N-aryl piperazine derivative and preparation method thereof and drug composition adopting N-aryl piperazine derivative as active ingredient
11/11/2009	CN101575335A Dehydrogenated silibinin substituted by meta-chlorobenzene formoxyl, preparation method and pharmaceutical applications thereof

1 ... 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 ... 1833